Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Primate cell – per se
Reexamination Certificate
2006-11-22
2009-12-15
Weber, Jon P (Department: 1657)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Primate cell, per se
C435S390000
Reexamination Certificate
active
07632678
ABSTRACT:
Disclosed are enriched preparations of neuroblastoma tumor initiating cells (NB TICs). The NB TICs are capable of self-renewal, initiating neuroblastoma tumor growth in vivo and are capable of being passaged in high frequency. These NB TICs have chromosomal abnormalities and are capable of giving rise to secondary tumor spheres. Methods are also disclosed for preparing the enriched preparations of NB TICs, such as from neuroblastoma tumor tissue and metastasized bone marrow. Also disclosed are methods of screening candidate substances to identify therapeutic agents for the treatment of neuroblastoma. Methods are also provided for screening a sample for neuroblastoma, as well as for screening a sample to identify the stage of neuroblastoma present. Kits are also provided for selecting appropriate anti-neuroblastoma compounds for a patient, and utilize isolated compositions of the patients' neuroblastoma tumor initiating cells. In this manner, a customized medicinal profile for the patient may be devised.
REFERENCES:
patent: 4628062 (1986-12-01), Opitz et al.
patent: 6787355 (2004-09-01), Miller et al.
patent: 2003/0203856 (2003-10-01), Rosazza et al.
patent: 2005/0202019 (2005-09-01), Murphy et al.
Hirschmann-Jax et al. A Distinct “Side Population” of Cells With High Drug Efflux Capacity in Human Tumor Cells; Proceedings of the National Academy of Sciences, vol. 101, No. 39 (2004) pp. 14228-14233.
Walton et al. Characteristics of Stem Cells From Human Neuroblastoma Cell Lines and in Tumors; Neoplasia, vol. 6, No. 6 (2004) pp. 838-845.
Gazitt et al. Isolation and Characterization of an Early T-Helper/Inducer Cell Line With a Unique Pattern of Surface Phenotype, Constitutive Cytokine Secretion and MYC Oncogene Expression; Leukemia, vol. 7, No. 12 (1993) pp. 2034-2044.
Brodeur, G. “Neurblastoma: Biological Insight into a Clinical Enigma.”Nature Reviews: Cancer, 3:203-216, (Mar. 2003).
Mars, J. “The Biological Basis for Neurblastoma Heterogeneity and Risk Stratisfication.”Current Opinions in Pediatrics, 17: 7-13, (2005).
Van Limpt et al., “Phox2B Mutations and the Delta-Notch Pathway in Neuroblastoma.”Cancer Letters, 228: 59-63, (2005).
Pardal, et al. “Applying the Principles of Stem-Cell Biology to Cancer.”Nature Reviews: Cancer, 3: 895-902, (Dec. 2003).
Beachy, et al. “Tissue Repair and Stem Cell Renewal in Carcinogenesis.”Nature, 432:324-331, (Nov. 2004).
Warner, et al. “Concepts of Human Leukemic Development.”Oncogene, 23: 7164-7177, (2004).
Hamburger, A. & Salmon, S. “Primary Bioassay of Human Myeloma Stem Cells.”The Journal of Clinical Investigation, 60: 846-854, (Oct. 1977).
Heppner, G. “Tumor Heterogeneity.”Perspectives in Cancer Research, 44:2259-2265, (Jun. 1984).
Singh, et al. “Cancer Stem Cells in Nervous System Tumors.”Oncogene, 23:7267-7273, (2004).
Al-Hajj, M. & Clarke, M. “Self-Renewal and Solid Tumor Stem Cells.”Oncogene, 23:7274-7282, (2004).
Lapidot, et al. “A Cell Initiating Human Acute Myeloid Leukaemia after Transportation into SCID Mice.”Letters to Nature, 367:645-648, (Feb. 1994).
Bonnet, D. & Dick, J. “Human Acute Myeloid Leukemia is Organized as a Hierarchy that Originates from a Primitive Hematopoietic Cell.”Nature Medicine, 3:730-737, (Jul. 1997).
Al-Hajj, et al. “Perspective Identification of Tumorigenic Breast Cancer Cells.”Proceedings of the National Academy of the Sciences USA, 100:3983-3988, (Mar. 2003).
Singh, et al. “Identification of Human Brain Tumour Initiating Cells.”Nature, 432:396-401, (Nov. 2004).
Van Noesel, et al. “Neuroblastoma 4S: A Heterogeneous Disease with Variable Risk Factors and Treatment Strategies.”Cancer, 80:834-843, (Sep. 1997).
Toma, et al. “Isolation of Multipotent Adult Stem Cells from the Dermis of Mammalian Skin.”Nature Cell Biology, 3:778-784, (Sep. 2001).
Fernandes, et al. “A Dermal Niche for Multipotent Adult Skin-Derived Precursor Cells.”Nature Cell Biology, 6:1082-1093, (Nov. 2004).
Toma, et al. “Isolation and Characterization of Multipotent Skin-Derived Precursors from Human Skin.”Stem Cells, 23:727-737, (2005).
Christiansen, et al. “Molecular Control of Neural Crest Formation, Migration and Differentiation.”Current Opinion in Cell Biology, 12:719-724, (2000).
Ambros, et al. “Disseminated Tumor Cells in the Bone Marrow—Chances and Consequences of Microscopical Detection Methods.”Cancer Letters, 197:29-34, (2003).
Miettinen, et al. “Monoclonal Antibody NB84 in the Differential Diagnosis of Neuroblastoma and Other Small Round Cell Tumors.”The American Journal of Surgical Pathology, 22:327-232, (1998).
Labrosse, et al. “Catecholamine Metabolism in Neuroblastoma.”J Natl Cancer Inst, 57:633-638, (Sep. 1976).
Barnabe-Heider, F & Miller, F. “Endogenously Produced Neurotrophins Regulate Survival and Differentiation of Cortical Progenitors via Distinct Signaling Pathways.”The Journal of Neuroscience, 23(12):5149-5160, (Jun. 2003).
Marsh, et al. “SHP-1 Negatively Regulates Neuronal Survival by Functioning as a TrkA Phosphatase.”The Journal of Cell Biology, 163(5):999-1010, (2003).
Lo Piccolo, et al. “GD2 Synthase: A New Molecular Marker for Detecting Neuroblastoma.”Cancer, 92(4):924-931, (Aug. 2001).
Fernandes, et al. “Analysis of the Neurogenic Potential of Multipotent Skin-Derived Precursors.”Experimental Neurology, 201:32-48, (2006).
Hafer, et al. “Neuroblastoma cells can express the hematopoietic progenitor cell antigen CD34 as detected at surface protein and mRNA level.”Journal of Neuroimmunology, 96:201-206, (1999).
Khanna, et al. “Biologically Relevant Orthotopic Neuroblastoma Xenograft Models: Primary Adrenal Tumor Growth and Spontaneous Distant Metastasis.” In Vivo, 16:77-86, (2002).
Nakagawara, A & Ohira, M. “Comprehensive genomics linking between neural development and cancer: neuroblastoma as a model.”Cancer Letters, 204:213-224, (2004).
Ohira, et al. “Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas.”Cancer Cell, 7:337-350, (Apr. 2005).
Weiss, et al. “Targeted expression of MYCN causes neuroblastoma in transgenic mice.”The Embo Journal, 16(11):2985-2995, (1997).
Elshamy, et al. “Growth Arrest Failure, G1 Restriction Point Override, and S Phase Death of Sensory Precursor Cells in the Absence of Neurotrophin-3.”Neuron: 21:1003-1015, (Nov. 1998).
Lasorella, et al. “Id2 Is Critical for Cellular Proliferation and Is the Oncogenic Effector of N-Myc in Human Neuroblastoma.”Cancer Research, 62:301-306, (Jan. 2002).
Valsesia-Whittmann, et al. “Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells.”Cancer Cell, 6:625-630, (Dec. 2004).
Dubreuil, et al. “The Phox2b transcription factor coordinately regulates neuronal cell cycle exit and identity.”Development, 127:5191:5201, (2000).
Pattyn, et al. “Specification of the Central Noradrenergic Phenotype by the Homeobox Gene Phox2b.”Mollecular and Cellular Neuroscience, 15:235-243, (2000).
Pozniak, etal. “An Anti-Apoptotic Role for the p53 Family Member, p73, During Developmental Neuron Death.”Science, 289:304-306, (Jul. 2000).
Casciano, et al. “Expression of ΔNp73 is a molecular marker for adverse outcome in neuroblastoma patients.”Cell Death and Differentiation, 9:246-251, (2002).
Matsumoto, et al. “Expression of Brain-derived Neurotrophic Factor and p145TrkBAffects Survival, Differentiation, and Invasiveness of Human Neuroblastoma Cells.”Cancer Research, 55:1798-1806, (Apr. 1995).
Jaboin, et al. “Brain-derived Neurotrophic Factor Activation of TrkB Protects Neuroblastoma Cells
Datti Alessandro
Hansford Loen M.
Kaplan David R.
Miller Freda M.
Smith Kristen M.
Jagtiani Ajay A.
Martin Paul C.
The Hospital for Sick Children
Vedder Price P.C.
Weber Jon P
LandOfFree
Cancer stem cells and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer stem cells and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer stem cells and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4061171